Qualigen therapeutics announces pre-ind feedback from u.s. food and drug administration regarding qn-302 for the treatment of g4-targeted advanced solid tumors

Carlsbad, calif., dec. 07, 2022 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces that it has received feedback from the fda following a pre-investigational new drug (pre-ind) interaction regarding the development pathway to a phase 1 clinical trial of qn-302 for the treatment of g4-targeted advanced solid tumors. the purpose of the pre-ind interaction was to inform the proposed content of the company's ind application and request guidance from the division on specific questions prior to submission of the ind application. the fda's response provides qualigen with clear guidance for formally submitting an ind application for qn-302 after accounting for the agency's comments and suggestions.
QLGN Ratings Summary
QLGN Quant Ranking